Review Update on Pneumococcal Conjugate Vaccine: A New Hope for Reduction of Pneumococcal Disease in Bangladesh
Pneumococcal diseases are the common and widely distributed disease in the world. It causes various mortality and morbidity every year, mainly in the developing countries. Pneumococcal conjugate vaccine (PCV) is the new vaccine against all invasive pneumococcal diseases. PCV10 and PCV13 are the available preparation in worldwide. It is safe, highly antigenic and minimal side effects. In Bangladesh, PCV is included in EPI schedule from April 2015. The current preparation is Synforix PCV10, which is given intramuscularly with the pentavalent vaccine in EPI schedule. In conclusion, the assessment of PCV impact in Bangladesh requires national and regional level surveillance and the introduction of PCV in EPI will reduce the mortality and morbidity of the pneumococcal disease.
Bangladesh J Infect Dis 2015;2(1):19-22
Copyright (c) 2017 Jannatul Fardows, Abu Bakar Siddique, Nasren Farhana, Tasmine Binte Islam
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright on any research article in the Bangladesh Journal of Infectious Diseases is retained by the author(s).
The authors grant the Bangladesh Infection Research Association a license to publish the article and identify itself as the original publisher.
Articles in the Bangladesh Journal of Infectious Diseases are Open Access articles published under the Creative Commons CC BY-NC License (https://creativecommons.org/licenses/by-nc/4.0/)
This license permits use, distribution and reproduction in any medium, provided the original work is properly cited, and it is not used for commercial purposes.